EMEA-001219-PIP01-11-M06 - paediatric investigation plan
dolutegravir
abacavir
lamivudine
PIPHuman
ViiV Healthcare UK Limited
E-mail: eu.paediatric-plans@gsk.com
Tel: +1 4388998201
P/0038/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M06)